Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy

Abstract

IntroductionSchizophrenia is a chronic and debilitating mental disorder that affects the patient’s and their family’s quality of life, as well as financial costs and health care settings. Despite the variety of available antipsychotics, optimal treatment outcomes are not always achieved. Novel drugs, such as iloperidone, can provide more effective, tolerable and safer strategies.AimTo review the evidence for the clinical impact of iloperidone on the treatment of patients with schizophrenia.Evidence reviewClinical trials, observational studies and meta-analyses reached a common consensus that iloperidone is as effective as haloperidol, risperidone and ziprasidone in reducing schizophrenia symptoms. Similar amounts of adverse events and discontinuations were observed with iloperidone compared to placebo and active treatments. Common adverse events are mild and include dizziness, hypotension, dry mouth and weight gain. Iloperidone can induce extension of QTc interval, and clinicians should be aware of its contraindications. In long-term trials, iloperidone also showed promising safety and tolerability profiles. The low propensity to cause akathisia, extrapyramidal symptoms (EPS), increased prolactin levels or changes to metabolic laboratory parameters support its use in practice. Results showed that iloperidone prevents relapse in stabilized patients, with a time to relapse superior to placebo and similar to haloperidol. Patients using a prior antipsychotic (eg, risperidone and aripiprazole) can easily switch to iloperidone with no serious impact on safety or efficacy. However, the acquisition costs of iloperidone may hamper its use. Further evidence comparing iloperidone with other antipsychotics, and pharmacoeconomic studies would be welcome.Place in therapyConsidering just the clinical profile of iloperidone, it represents a promising drug for treating schizophrenia, particularly in patients who are intolerant to previous antipsychotics, as well as being suitable as first-line therapy. Cost-effectiveness comparisons are needed to justify its use in clinical practice.

Network-based stage-specific drug repurposing for Alzheimer’s disease

“…As an antipsychotic, this drug could be a potential candidate for symptom-relief for AD since antipsychotics are often prescribed to patients. It shows promising efficacy and safety profile compared to other drugs [52] .…”

Lithium and Atypical Antipsychotics: The Possible WNT/β Pathway Target in Glaucoma

“…Iloperidone, a AAP drug, presents binding affinity to serotoninergic (5-HT2A, 5-HT6 and 5-HT7), dopaminergic (D2, D3 and D4) and adrenergic (α1 and α2C) receptors in the CNS) [ 142 ]. Iloperidone can inhibit serotonergic 5HT2A receptor (J-13) and adrenergic alpha 1A receptor [ 143 , 144 ] and is responsible for hypotension [ 145 ]. In dose 0.03 mg/Kg i.p., Iloperidone present reduced blood pressure within the 10 min of administration for animals [ 146 ].…”

Chronic Effects of Loxapine, Iloperidone, Paliperidone on Mice Isolated Vas Deferens Contractility

“…9 Iloperidone has a high affinity for both D2 and 5HT2A receptors. 10 Paliperidone or 9-hydroxy risperidone is the major active metabolite of risperidone. Paliperidone acts on dopamine D2 and serotonin 5HT2A receptors as an antagonist and also antagonizes the α1-and α2adrenergic receptors and H1-histaminergic receptors.…”